Artal Group’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Artal Group’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-258,687	Closed	-$5.99M	–	136
2023 Q1	$5.99M	Buy	+258,687	New	+$6.17M	0.36%	58
2022 Q1	–	Sell	-180,500	Closed	-$2.94M	–	152
2021 Q4	$2.94M	Hold	180,500	–	–	0.08%	123
2021 Q3	$2.3M	Hold	180,500	–	–	0.05%	132
2021 Q2	$2.55M	Hold	180,500	–	–	0.05%	134
2021 Q1	$2.81M	Hold	180,500	–	–	0.05%	135
2020 Q4	$2.86M	Hold	180,500	–	–	0.06%	118
2020 Q3	$2.19M	Sell	180,500 -9,500	-5%	-$127K	0.05%	121
2020 Q2	$2.19M	Sell	190,000 -10,000	-5%	-$138K	0.06%	123
2020 Q1	$2.74M	Hold	200,000	–	–	0.12%	95
2019 Q4	$1.18M	Hold	200,000	–	–	0.05%	96
2019 Q3	$1.06M	Hold	200,000	–	–	0.04%	100
2019 Q2	$1.54M	Hold	200,000	–	–	0.06%	96
2019 Q1	$3.98M	Hold	200,000	–	–	0.16%	82
2018 Q4	$2.64M	Buy	200,000 +90,000	+82%	+$1.8M	0.1%	88
2018 Q3	$4.04M	Hold	110,000	–	–	0.11%	81
2018 Q2	$3.85M	Hold	110,000	–	–	0.08%	76
2018 Q1	$5.12M	Buy	110,000 +70,000	+175%	+$2.56M	0.06%	68
2017 Q4	$1.5M	Hold	40,000	–	–	0.02%	106
2017 Q3	$2.13M	Buy	40,000 +20,000	+100%	+$1.19M	0.04%	91
2017 Q2	$1.14M	Hold	20,000	–	–	0.02%	102
2017 Q1	$1.07M	Hold	20,000	–	–	0.02%	88
2016 Q4	$1.14M	Hold	20,000	–	–	0.03%	85
2016 Q3	$1.24M	Buy	+20,000	New	+$1.41M	0.02%	90

Other funds holding KDNY

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group's KDNY Position: Q2 2023 in Review

Artal Group sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q2 2023, closing a stake of 258,687 shares — an estimated $5.99M sold.

Artal Group first reported a position in KDNY in Q3 2016 and held it in 23 quarters. The position peaked at $5.99M in Q1 2023. 185 funds tracked by Wall St. Rank hold KDNY as of Q2 2023.

Artal Group reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Artal Group sold 258,687 Chinook Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $5.99M.
Artal Group first reported a position in Chinook Therapeutics, Inc. Common Stock in Q3 2016 and held it in 23 quarters.
Artal Group's Chinook Therapeutics, Inc. Common Stock position peaked at $5.99M in Q1 2023.
185 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.